Few large-cap stocks split investors as cleanly as Pfizer. One side sees a cheap drugmaker paying a fat dividend. The other sees a shrinking revenue base propped up by a payout that may not survive the decade.
Both sides are looking at the same company. They just weigh the patent cliff differently.
Where the Stock Sits Today
Pfizer trades around $25 a share, in the lower half of its range over the past year and well off the highs it touched during the pandemic. The market value sits around $144 billion.
The dividend is the headline. Pfizer pays $1.72 a share each year, a yield of roughly 6.8% at the current price. The company has lifted that payout every year since 2010. For an income investor, almost 7% from a company this size is rare.
The valuation is the second hook. Pfizer guides for adjusted earnings of $2.80 to $3.00 a share this year. That puts the stock at roughly nine times forward earnings. The broad market trades closer to 22 times. Wall Street's average price target sits near $27, only modestly above where shares trade now.
So the bull and the bear start from agreement: the stock is cheap and the yield is large. The fight is over why.
The Bull Case
The bull argument is that the market is paying Pfizer for a decline that may not be as steep as the price implies.
At nine times earnings with a 6.8% yield, the stock is priced like a business in permanent retreat. But Pfizer still generates real cash. Free cash flow yield runs near 6.6%, and the dividend costs less than 60% of adjusted earnings. On that measure, the payout has room.
The growth pivot is the other half of the case. Pfizer spent $43 billion to buy Seagen, a cancer-drug specialist, and the deal pushed oncology to the center of the company. It then added Metsera for about $7 billion to enter the obesity market. Management plans to start roughly 20 pivotal trials this year, including ten for the long-acting obesity assets it bought.
If even a few of those programs land, the new revenue could offset the drugs rolling off patent. The bull does not need a blockbuster. The bull needs the decline to flatten while the dividend pays them to wait.
The Bear Case
The bear case is simpler and harder to argue with: the core is eroding faster than the pipeline can replace it.
Eliquis, the blood thinner that is one of Pfizer's largest products, lost its exclusivity in Europe in May. Ibrance, Xtandi, and Xeljanz all face the same fate between now and 2030. According to reported estimates, patent expirations could strip $17 billion to $18 billion in annual revenue from the company across 2026 through 2028.
That is happening on top of a COVID hangover. Sales of the Comirnaty vaccine and the Paxlovid treatment have fallen sharply from their pandemic peaks, and they keep sliding. Pfizer's 2026 revenue guidance came in below what analysts wanted, and patent losses alone are expected to cut about $1.5 billion this year.
The balance sheet adds pressure. The Seagen deal was funded largely with debt, and net debt now runs close to 3.7 times earnings before interest, taxes, and the rest. That is high for a company also committed to a rising dividend.
The Dividend Is the Whole Argument
For most people looking at this stock, the question is not really growth. It is whether the dividend is safe.
Here the numbers cut both ways. Measured against adjusted earnings, the payout looks comfortable. Measured against free cash flow, it is tight. Last year the company's free cash flow roughly matched what it paid in dividends, which leaves little cushion if business weakens or restructuring costs run higher than planned.
A board that has raised the dividend for more than a decade does not cut it casually. The streak itself is an asset Pfizer is unlikely to surrender without a fight. But "unlikely to cut" is not the same as "certain to grow," and the bear would argue the raises get smaller from here.
The Pipeline Bet
The case ultimately rests on one question: can the oncology and obesity buildout outrun the patent cliff?
Oncology is the clearer story. Seagen gave Pfizer a set of approved cancer drugs and a technology platform, and that franchise is growing while the older products fade. Obesity is the lottery ticket. Pfizer already stumbled once, discontinuing its experimental pill danuglipron in 2025, and the Metsera assets are not expected to reach a first approval until 2028.
That timeline matters. The patent losses are happening now. The replacements, especially in obesity, are years out. Compare that to Eli Lilly, which already dominates the obesity market and trades north of 30 times forward earnings. The market is paying a premium for proven growth and a discount for the promise of it.
What to Watch
Pfizer is a bet on time. The dividend pays investors to wait while management tries to rebuild faster than its old drugs disappear.
The numbers to track are not the daily price. They are the trial readouts from the Metsera obesity programs, the pace of oncology growth versus the Eliquis decline, and the size of the next dividend raise. A small increase would signal the board is protecting cash. A normal increase would signal confidence.
The cheap valuation and the high yield are real. So is the patent cliff. Anyone buying Pfizer is deciding which of those facts matters more over the next three years.
